Drug Trial Radar · NCT06594874
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
Oct 31, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .
Conditions
- Non-Small Cell Lung Cancer
- Advanced Solid Tumors
Interventions
HS-10370Drug
HS-10370 administered orally every day
AdebrelimabDrug
Administered intravenously every 21 days; dose by label.
CisplatinDrug
Administered intravenously every 21 days; dose by label.
CarboplatinDrug
Administered intravenously every 21 days; dose by label.
PemetrexedDrug
Administered intravenously every 21 days; dose by label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Event(s) (AEs)Time frame: From Cycle 1 Day 1 to first documented progression of disease or death from any cause, approximately 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.